Nemes Rush Group
RCKT icon

Nemes Rush Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Nemes Rush Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.89K Buy
+1,100
New +$3.81K ﹤0.01% 723

Other funds holding RCKT

Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Monaco Asset Management
Monaco Asset Management Monaco $818M AUM 32.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nemes Rush Group's RCKT Position: Q3 2026 in Review

Nemes Rush Group opened a new position in Rocket Pharmaceuticals (RCKT) in Q3 2026: 1,100 shares worth $2.89K. The stake represents ﹤0.01% of the portfolio and ranks #723 among its holdings.

74 funds tracked by Wall St. Rank hold RCKT as of Q3 2026.

  • Nemes Rush Group held 1,100 shares of Rocket Pharmaceuticals worth $2.89K as of Q3 2026.
  • Rocket Pharmaceuticals was a new Nemes Rush Group position in Q3 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of Nemes Rush Group's portfolio in Q3 2026, its #723 holding.
  • 74 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.